ClinicalTrials.gg
CompletedNCT07249567Updated Oct 29, 2026

Comparison of Patients With COPD and PRISM

An observational study in COPD, sponsored by Karabuk University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Karabuk University · Observational

How we know

Updated Oct 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
91
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey — 58 open to participants now, 68 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Turkey.

Enrollment
27th of 60
91 · median 77
Started
2025
with 26 others
Observational
60 of 248
19 open now
Registered
223rd of 248
by date

Among the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, this one is the 27th largest by enrollment of the 60 observational ones that give a count, is one of 27 that started in 2025, is one of 60 observational ones, and was the 223rd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

58 of the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, or all of them as a file.
02

Study summary

COPD is a preventable and treatable lung disease characterized by persistent and progressive airflow limitation. PRISm, on the other hand, is a spirometry pattern that does not meet COPD diagnostic criteria despite symptoms and functional impairments, but requires maintenance. PRISm can predispose to the development of COPD and exacerbations, and can reduce exercise capacity by reducing respiratory function and oxygen consumption. There are no studies in the literature comparing respiratory muscle strength, peripheral muscle strength, and oxygenation in PRISm, COPD, and healthy individuals. Therefore, this study aimed to evaluate these parameters and compare them with healthy individuals.

Read the detailed description

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable multisystem lung disease characterized by chronic respiratory symptoms (dyspnea, cough, sputum production, and/or exacerbations) due to airway abnormalities, causing persistent and often progressive airflow limitation. PRISm is defined as a spirometry pattern that is not always a stable phenotype but should be considered "sick" because symptoms and/or functional and/or structural abnormalities are present and therefore require care and treatment. Recently, PRISm has been identified as a subtype more prone to developing COPD or experiencing acute exacerbations. In addition to affecting the respiratory muscles, PRISm's effects on respiratory function lead to decreased body oxygen consumption and increased dyspnea. PRISm can also lead to decreased exercise capacity due to the respiratory problems and dyspnea it causes. Although there are not enough studies in the literature investigating exercise capacity and lung functions on behalf of PRISm, no previous study comparing respiratory muscle strength, peripheral muscle strength and oxygenation in PRISm, COPD and healthy individuals has been found.

03

Conditions studied

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with COPD and PRSIm will be included and compared with healthy controls

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For the group:

  • Being >40 years old,
  • Being diagnosed with COPD,
  • Being clinically stable,
  • Volunteering to participate in the study.

For the PRISm group:

  • Being >40 years old,
  • Being diagnosed with PRISm,
  • Volunteering to participate in the study.

For the healthy control group:

  • Being >40 years old,
  • Volunteering to participate in the study.

Exclusion criteria

Exclusion Criteria:

For the group:

  • Having severe orthopedic, neurological, or cardiac diseases,
  • Being in a COPD exacerbation,
  • Having a comorbid lung disease,
  • Being on clinically unstable medication,
  • Voluntarily not participating in the study.

For the PRISm group:

  • Being diagnosed with COPD,
  • Having severe orthopedic, neurological, or cardiac diseases,
  • Having a comorbid lung disease,
  • Voluntarily not participating in the study.

For the healthy control group:

  • Having a known chronic disease,
  • Voluntarily not participating in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
91 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with COPD

    Patients with chronic obstructive pulmonary disease will be included.

  • Patients with PRISm

    Patients with preserved ratio impaired spirometry will be included.

  • Control

    Healthy controls will be included.

06

What researchers measure

Primary outcomes

  1. Upper extremity exercise capacity

    Upper extremity exercise capacity will be evaluated with the six-minute pegboard and ring test (6-PBRT).

    Time frame: Baseline

  2. Lower extremity exercise capacity

    Lower extremity exercise capacity will be evaluated with six- minute walking test.

    Time frame: Baseline

  3. Peripheral muscle strength

    Peripheral muscle strength will be evaluated with a dynamometer.

    Time frame: Baseline

  4. Muscle oxygenation

    Muscle oxygenation assessment will be performed using the Moxy monitor (Moxy, Fortiori Design LLC, Minnesota, USA).

    Time frame: Baseline

  5. Respiratory Muscle Strength

    Maximal inspiratory (MIP) and maximal expiratory (MEP) pressures expressing respiratory muscle strength will be evaluated.

    Time frame: Baseline

  6. Respiratory Muscle Endurance

    Respiratory muscle endurance will be assessed by the POWERbreathe Wellness (POWERbreathe, Inspiratory Muscle Training (IMT) Technologies Ltd., Birmingham, UK) device and the respiratory muscle endurance test at increased threshold load.

    Time frame: Baseline

  7. Dyspnea

    Dyspnea is assessed with the modified Medical Research Council (mMRC) dyspnea scale. As the score increases, shortness of breath increases.

    Time frame: Baseline

  8. Clinical symptoms

    The COPD Assessment Test will be evaluated. This scale scored on a 0-5 point scale to assess symptoms associated with COPD. As the score increases, the symptom increases.

    Time frame: Baseline

Secondary outcomes

  1. Pulmonary function (Forced vital capacity (FVC)

    Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Forced vital capacity (FVC) will be measured.

    Time frame: Baseline

  2. Pulmonary function (Forced expiratory volume in the first second (FEV1)

    Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Forced expiratory volume in the first second (FEV1) will be measured.

    Time frame: Baseline

  3. Pulmonary function (FEV1 / FVC)

    Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. FEV1 / FVC will be measured.

    Time frame: Baseline

  4. Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%))

    Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Flow rate 25-75% of forced expiratory volume (FEF 25-75%) will be measured.

    Time frame: Baseline

  5. Pulmonary function (Peak flow rate (PEF))

    Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society criteria. Peak flow rate (PEF) will be measured.

    Time frame: Baseline

07

Study locations

1 site
  • Karabuk University, Physiotherapy and Rehabilitation Application and Research Center
    Karabük, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2025 to primary completion in Mar 2026, 5 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Sep 2026 → Mar 2026 and completion Nov 2026 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartActual
Oct 5, 2025
Primary completionActual
Mar 5, 2026was Sep 2026
CompletionActual
Mar 30, 2026was Nov 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 29, 2026
Primary completion
Sep 5, 2026→Mar 5, 2026 (actual)
Oct 29, 2026
Study completion
Nov 30, 2026→Mar 30, 2026 (actual)
Oct 29, 2026
Enrollment
60 (estimated)→91 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Completed
    Primary completion Sep 5, 2026→Mar 5, 2026 (now actual)
    Study completion Nov 30, 2026→Mar 30, 2026 (now actual)
    Enrollment 60 (estimated)→91 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07249567
Lead sponsor
Karabuk University
Responsible party
Musa Güneş (Principal Investigator, PhD, Karabuk University) — Principal investigator
First posted
Nov 25, 2025
Start date
Oct 5, 2025
Primary completion
Mar 5, 2026
Completion
Mar 30, 2026
Last update
Oct 29, 2026

Study contacts

Musa Güneş, PhD
principal investigator · Karabuk University
Rabia Hande Avcı, MD
principal investigator · Karabuk University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion